Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.510 -0.050 (-3.21%)
Streaming Delayed Price Updated: 10:52 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
Via ACCESS Newswire
NanoViricides, Inc. Has Filed its Quarterly Report
Via ACCESS Newswire
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Clears Ethics Review for Phase II Mpox Trial in DRC
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present at D. Boral Capital Inaugural Global Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Development with Broad-Spectrum Antiviral NV-387
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
Via ACCESS Newswire
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
Via Investor Brand Network
Topics Intellectual Property World Trade
Exposures COVID-19 Intellectual Property Tariff
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
Via Investor Brand Network
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Showcases NV-387’s Broad-Spectrum Antiviral Potential at MicroCap Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Partners with CRO to Advance NV-387 Antiviral Drug to Phase II Trials
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides Engages CRO for Phase II Clinical Trial
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Broad-Spectrum Antiviral Innovations at Biotech Showcase 2025
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as a Broad-Spectrum Antiviral Solution to Emerging Threats
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Touts NV-387 as Key Defense Against Potential Bird Flu Pandemic
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
Via ACCESSWIRE
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.